Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Avastin Approved for Treatment of Breast Cancer in Combination with Paclitaxel
October 13, 2011
-
ORGANIZATION 17 Additional Products Eligible for PDSC Development Subsidies
October 12, 2011
-
BUSINESS Takeda Bio Initiates P1/2 Trial of Malignant Lymphoma Treatment in Japan
October 12, 2011
-
ORGANIZATION Industry to Seek Additional Data for Full Introduction of Premium for New Drug Development: Mr Negi
October 11, 2011
-
BUSINESS Takeda Discontinues Development of Insomnia Drug Ramelteon in Europe
October 11, 2011
-
BUSINESS Takeda to Offer Information on Actos for Prescribing Doctors
October 7, 2011
-
BUSINESS Mediceo Aiming for 20% Market Share in Hokkaido within 3 Years: President Watanabe
October 7, 2011
-
BUSINESS Aiming for 6% Yearly Growth by Rivaroxaban Launching: Bayer AG
October 6, 2011
-
REGULATORY Number of Pharmacies Qualifying for Premiums for GE Drug Dispensing Systems Down in 2010
October 6, 2011
-
BUSINESS Takeda President Hasegawa Says Innovation Will Take Place in Developing Countries
October 5, 2011
-
BUSINESS Ono and Germany’s Merck Enter into License Agreements to Boost Priority Fields
October 5, 2011
-
ORGANIZATION Leading Biotech Clusters in Osaka, Munich Sign Partnership Agreement
October 5, 2011
-
REGULATORY FPMAJ States Difficulty in Identifying Anticancer Drugs in Terms of Adverse Reactions
October 4, 2011
-
BUSINESS Mochida’s New 3-Year Business Plan Aims for Sales of ¥100 Bil. in FY2013
October 4, 2011
-
BUSINESS Takeda Completes Acquisition of Nycomed, Global Rx Sales Ranking Up to 12th
October 3, 2011
-
ORGANIZATION Takeda “Will Be Able to Get Through” Power Shortages: Mr Hasegawa
October 3, 2011
-
ORGANIZATION “Permanent Introduction of Premium for New Drug Development Premature”: CSIMC Member Adachi
September 30, 2011
-
BUSINESS MS Pharma Forms Strategic Alliance with Korean Company in Biosimilars
September 30, 2011
-
BUSINESS Takeda President Hasegawa Eyes Joint Research with Chinese Companies
September 29, 2011
-
REGULATORY CSIMC’s Committee to Assess Premium for New Drug Development Based on Results of Market Price Survey
September 29, 2011
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…